HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients
NCT ID: NCT02908763
Last Updated: 2018-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
200 participants
INTERVENTIONAL
2016-08-31
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg
NCT02893124
The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg
NCT02745704
The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg
NCT02838810
HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated
NCT01471535
Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection
NCT02973646
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After giving informed consent, patients were treated with weekly subcutaneous injections of alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week. The use of other immune suppressive or regulatory drugs and other antiviral drugs was prohibited during the course of the study.
In this study, treatment endpoint was HBsAg loss(\<0.05 IU/mL) and anti-HBs positive(\>10 milli-International unit(mIU)/mL) defined as seroconversion. Depending on the decline of HBsAg level, treatment was either continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in case of nonresponse. Treatment was proceeded if HBsAg level continued to decline until HBsAg seroconversion was achieved and the anti-HBs level was above 200 mIU/ml. If the patients were not willing to extend treatment, the therapy was ended at the time of HBsAg loss, or stopped without further decline of HBsAg levels.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pegylated interferon group
Low replicative chronic HBV infection patients with HBsAg \<1000 IU/ mL and HBV DNA\<2000 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
peginterferon alfa
peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
Observing Group
Only observing and following up in this group.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
peginterferon alfa
peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Hepatitis B surface antibody (HBsAb) negative.
3. Hepatitis B e antigen (HBeAg) negative.
4. Hepatitis B virus DNA \<2000 IU/mL.
5. Absence of previous antiviral therapy.
Exclusion Criteria
2. Patients with liver cirrhosis, Hepatocellular Carcinoma or other malignancies.
3. Patients with other factors causing liver diseases.
4. Pregnant and lactating women.
5. Patients with concomitant HIV infection or congenital immune deficiency diseases.
6. Patients with diabetes, autoimmune diseases.
7. Patients with important organ dysfunctions.
8. Patients with mental illness.
9. Patients who receive antineoplastic or immunomodulatory therapy in the past 12 months.
10. Patients who can't come back to clinic for follow-up on schedule.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University
OTHER
Huazhong University of Science and Technology
OTHER
Nanchang University
OTHER
Huizhou Municipal Central Hospital
OTHER
First People's Hospital, Shunde China
OTHER
Shenzhen Third People's Hospital
OTHER
First People's Hospital of Foshan
OTHER
Tang-Du Hospital
OTHER
First Affiliated Hospital of Kunming Medical University
OTHER
Yuebei People's Hospital
OTHER
Third Affiliated Hospital, Sun Yat-Sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhiliang Gao
chief director of department of infectious disease
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Infectious Diseases, The Third Affliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3rd-SYSU-I-Cure-4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.